Original InvestigationFinerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Under a Creative Commons license
open access
Central Illustration
Key Words
chronic kidney disease
clinical trial
finerenone
mineralocorticoid receptor antagonist
new-onset atrial fibrillation
type 2 diabetes
Abbreviations and Acronyms
AFF
atrial fibrillation or flutter
CI
confidence interval
CKD
chronic kidney disease
ECG
electrocardiogram
eGFR
estimated glomerular filtration rate
HR
hazard ratio
MRA
mineralocorticoid receptor antagonist
T2D
type 2 diabetes
UACR
urine albumin-to-creatinine ratio
Cited by (0)
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.